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Abstract:  
Mechanistic disease stratification will be crucial to develop a precision medicine approach for 
future disease modifying therapy in sporadic Parkinson’s disease (sPD). Mitochondrial and 
lysosomal dysfunction are key mechanisms in the pathogenesis of sPD and therefore promising 
targets for therapeutic intervention. We investigated mitochondrial and lysosomal function in 
skin fibroblasts of 100 sPD patients and 50 age-matched controls. A combination of cellular 
assays, RNA-seq based pathway analysis and genotyping was applied. Distinct subgroups with 
mitochondrial (mito-sPD) or lysosomal (lyso-sPD) dysfunction were identified. Mitochondrial 
dysfunction correlated with reduction in complex I and IV protein levels. RNA-seq based 
pathway analysis revealed marked activation of the lysosomal pathway with enrichment for 
lysosomal disease gene variants in lyso-sPD. Conversion of fibroblasts to induced neuronal 
progenitor cells and subsequent differentiation into tyrosine hydroxylase positive neurons 
confirmed and further enhanced both mitochondrial and lysosomal abnormalities. Treatment 
with ursodeoxycholic acid improved mitochondrial membrane potential and intracellular ATP 
levels even in sPD patient fibroblast lines with comparatively mild mitochondrial dysfunction. 
The results of our study suggest that in-depth phenotyping and focussed assessment of putative 
neuroprotective compounds in peripheral tissue are a promising approach towards disease 
stratification and precision medicine in sPD. 
 
Key words: 
Parkinson’s disease, disease stratification, fibroblasts, ursodeoxycholic acid, UDCA. 
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1. Introduction 
Parkinson’s disease (PD) continues to be a relentlessly progressive disorder. The failure of 
previous clinical trials investigating putative neuroprotective compounds for PD may be due 
to differences between patients in the underlying pathogenic mechanisms. Precision medicine 
is increasingly advocated as a promising strategy in the pursuit of neuroprotection in PD but 
would require the identification of distinct pathomechanisms in individual patients (Espay et 
al., 2017).  
We and others have identified distinct abnormalities of mitochondrial or lysosomal function 
and morphology in peripheral tissue of genetically stratified PD patient cohorts (Hockey et al., 
2015; Mortiboys et al., 2010; Mortiboys et al., 2008; Rakovic et al., 2011). Other groups have 
used PD-patient derived fibroblasts to demonstrate mitochondrial dysfunction in patients with 
more complex forms of Mendelian PD such as VPS13C (Lesage et al., 2016)  to investigate the 
interaction of PD genes such as the role of LRRK2 in the regulation of PINK1/Parkin-
dependent mitophagy (Bonello et al., 2019) or to study the physiological role of then newly 
discovered genes such as ATP13A2 (Dehay et al., 2012). We subsequently undertook the first 
drug screen in genetically stratified PD patient tissue and identified ursodeoxycholic acid 
(UDCA) as a promising novel neuroprotective compound (Mortiboys et al., 2013; Mortiboys 
et al., 2015). Similarly, a fibroblast-based approach was used to demonstrate that ambroxol 
increases glucosylceramidase activity in the tissue of PD patients with and without 
heterozygous glucocerebrosidase (GBA1) mutations (McNeill et al., 2014). Mitochondrial and 
lysosomal dysfunction are also key pathogenic mechanisms in sporadic PD (sPD) and therefore 
particularly promising therapeutic targets (Schapira et al., 2014; van der Brug et al., 2015). We 
hypothesised that mechanistic stratification for mitochondrial or lysosomal dysfunction in sPD 
peripheral tissue would allow the identification of mechanistically rather than clinically defined 
sPD subgroups.  The proposed tissue-based mechanistic stratification would facilitate a future 
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precision medicine approach which may dramatically enhance the likelihood of successful 














Abbreviations: GBA, glucocerebrosidase; DA, dopaminergic; DMEM, Dulbecco's Modified 
Eagle's medium; iNPC, induced neuronal progenitor cells; LRRK2, leucine-rich repeat kinase 
2; LSD, lysosomal storage disorder; lyso-PD, subgroup of PD patients with lysosomal 
dysfunction; mitochondrial membrane potential, MMP; mito-PD, subgroup of PD patients with 
mitochondrial dysfunction; Parkinson’s disease, PD; UDCA, ursodeoxycholic acid.  
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2. Materials and Methods 
2.1. Participant recruitment 
Participants were recruited from the Oxford Parkinson’s Disease Centre Discovery cohort (22 
control and 63 sPD patient participants (Szewczyk-Krolikowski et al., 2014), and from 
Sheffield Teaching Hospitals through the Sheffield Institute of Translational Neuroscience 
(SITraN) (28 control and 37 sPD patient participants). Skin punch biopsies were taken from 
participants with PD and healthy age-matched controls. The study was approved by the 
respective local institutional review boards. Written informed consent was obtained from all 
research participants included in this study.  
There was no difference in mean age between control and sPD participants (age in years ± 
standard deviation (SD): sPD patients 61±10.7 years; controls, 61±13.1 years).  The average 
age of disease onset in sPD patients was 58±11.3 years, with an average disease duration of 
4.26±3.65 years. All patients and controls were screened for four common Mendelian 
mutations associated with late onset PD: LRRK2G2019S and LRRK2R1441C/G as well as GBAN370S 
and GBAL444P. Three out of 100 patients were identified as mutation carriers, carrying 
LRRK2G2019S, GBAN370S or GBAL444P, respectively.  
Subsequent in-depth functional experiments were undertaken in the five sPD patients with the 
most marked reduction in ATP levels (mito-sPD) and also in the five patients with the most 
marked increase in the number of lysosomes (lyso-sPD). These stratified patient groups were 
matched with those control participants who were most closely age matched within the cohort. 
There was no difference in mean age for either the mito-sPD or the lyso-sPD group and the 
age-matched control groups (mito-sPD patients 60±6.0 years (n=5) and matched controls 
62±6.5 years (n=5); lyso-sPD patients 65±11.5 years (n=5) and matched controls 61±10.9 years 
(n=5). In addition we selected a group of 3 sPD patient fibroblast lines to convert into iNPC’s; 
the iNeuron sub group; these sPD patients were selected based upon having a mixed 
 6 
mitochondrial and lysosomal profile in fibroblasts; where both mitochondrial and lysosomal 
measurements were at least 2 SD outside of the control mean. The selection process of the 
controls was solely based on best-possible age-matching without taking the results from the 
screening assays for mitochondrial/lysosomal function into account. 
 
2.2. Fibroblast culture 
Primary fibroblast cells were cultured continuously in high glucose (4500 mg/L) Dulbecco's 
Modified Eagle's medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich), 100 IU/mL penicillin, 100 µg/mL streptomycin (Lonza), 1 mM sodium 
pyruvate (Sigma-Aldrich) and 50 µg/mL uridine (Alfa Aesar). Unless otherwise stated, 48 
hours prior to analysis, the glucose-containing media was exchanged for glucose-free DMEM 
(Gibco) with the same supplementation and in addition, 5 mM galactose (Sigma-Aldrich). All 
cells were assessed between passage 6-10.  
2.3. Mitochondrial function  
The mitochondrial membrane potential (MMP) and total cellular ATP levels were assessed as 
described previously (Mortiboys et al. 2008). The activity of the mitochondrial complexes I, II 
and IV were measured in fibroblasts using microplate activity assays (Abcam; ab109721, 
ab109910, ab109908). The assays were performed according to the manufacturer’s instructions 
using 20-30 µg protein per well for each complex measurement. Complex activity readings 
were normalised to protein content. Sample protein concentrations were measured using the 
Pierce BCA Protein Assay Kit (#23227, Thermofisher).  
Mitochondrial complex protein content was determined by western blot. Cell pellets from 
fibroblasts were lysed in RIPA buffer (R0278, Sigma-Aldrich) on ice for 30min. Protein 
concentration of lysates was determined using Bradford reagent. After SDS-PAGE, protein 
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was transferred on PVDF. Membranes were probed with mouse total OXPHOS antibodies (a 
combination of antibodies against Complex I - NDUFB8 subunit; Complex II - SDHB subunit; 
Complex III - UQCRC2 subunit; Complex IV - COX2 subunit; and Complex V - ATP5A 
subunit; 1:1,000; ab110411, Abcam); rabbit anti-beta-Actin (1:5,000; ab8227, Abcam) used as 
a loading control; followed by incubation in secondary rabbit or mouse HRP-conjugated 
antibodies (1:10,000; Rabbit: Bio-Rad 1706515, Mouse: Bio-Rad1706516; Bio-Rad).   
 
2.4. Lysosomal function 
Fibroblasts were incubated for 1 hour with 100 nM LysoTracker® (Life Technologies) and 10 
µM Hoechst 33342 (Sigma-Aldrich). Images were captured on the IN Cell Analyzer 2000 and 
analysed using the paired Developer software (GE Healthcare) allowing for segmentation of 
lysosomes, nuclei and cell boundaries to quantify lysosomal parameters per cell. Subsequent 
validation of the LysoTracker-based lysosomal quantification was undertaken using LAMP2 
immunocytochemistry. Fibroblasts were fixed in 4% paraformaldehyde, permeabilized with 
0.01% Triton X-100 in TBS-T and incubated in primary mouse-Lamp2 antibody (18822, Santa 
Cruz), then with 488 anti-mouse secondary antibody (A-11001, Life Technologies). Lysosomal 
function was assessed by quantifying Cathepsin D activity, using a fluorometric assay kit 
(ab65302, Abcam) and following the user instructions. The lysis buffer supplied by Abcam 
was substituted for RIPA buffer (R0278, Sigma-Aldrich). Fluorescence signal was measured 
using Omega FLUOStar plate reader (BMG Labtech). Protein concentration was determined 
using PierceTM BCA protein assay kit (23225, ThermoFisher).  Cathepsin D activity slope was 




2.5. Differential gene expression analysis 
500 ng of high quality total RNA, with an RNA integrity number (RIN) of 9 or above, was 
used in the preparation of sequencing libraries using the NEB Ultra II Directional RNA Library 
Prep Kit (NEB catalogue number E7760), following the polyA mRNA workflow. Libraries 
were individually indexed and pooled for standard Illumina sequencing on the HiScan SQ 
platform. RNA-seq samples were pre-processed with RNA-seq pipeline bcbio 
(https://github.com/bcbio/bcbio-nextgen) using Salmon quantification (Patro et al., 2017) . 
Salmon counts for each transcript were rounded to the nearest integer, and passed through the 
R package DESeq2 to calculate differential gene expression. For both lysosomal and 
mitochondrial conditions, patient samples were compared against controls. The threshold for 
differential expression was set at adjusted p value < 0.05. Similarity between patient groups 
was assessed by gene overlap. Identification of PD-associated genes was conducted using the 
web tool VarElect (Stelzer et al., 2016) (ve.genecards.org) using the search term “Parkinson’s 
Disease” and either “mitochondria” or “lysosome” depending on the source of the input. 
Pathway enrichment of DEGs was conducted using the web interface EnrichR (Kuleshov et 
al., 2016).  
 
2.6. Genetic analysis 
144 research participants were successfully genotyped using the NeuroChip array. The 
NeuroChip array described by Blauwendraat C et al. (Blauwendraat et al., 2017) is based on a 
genome-wide genotyping array (Infinium HumanCore-24 v1.0) containing 306,670 tagging 
variants and a custom content that has been updated and extended with neurodegenerative 
disease-related custom content consisting of 179,467 variants. Quality control was carried out 
using plink (v1.90b3) (Purcell et al., 2007). To call genotypes from the raw data files imported 
into GenomeStudio (2.0), sample number was sufficient to generate robust clusters within a 
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larger cohort including 1679 samples and thus no pre-made cluster file was used.  4 samples 
were excluded for technical reasons. Among the remaining 146 individuals, we discarded two 
individuals with elevated missing data rates (> 3%), outlying heterozygosity rate (> 3 standard 
deviation) or for which the gender was unable to be imputed from genotype information on the 
X chromosome. Finally, we excluded calling genotypes for 11,913 variant positions with high 
missing date rate (>5%) or that did not pass Hardy-Weinberg test (p value < 10-5). The 
frequency of all putative damaging variants (category 2b: MAF<3%, CADD C-Score> 12.37) 
among 51 lysosomal disease (LSD) genes (Robak et al., 2017) was compared between patients 
and controls, using Fisher’s exact test. One patient with a LRRK2G2019S mutation was removed 
from further analysis. The NeuroChip array analysis did not identify any additional relevant 
changes in Mendelian PD genes (see Supplementary Table 1, PD gene variants). The complete, 
individualised data of the genetic analysis are not publicly available due to the risk of 
patient/research participant identification but they are available from the corresponding author 
on reasonable request.  
 
2.7. Generation of TH-positive neurons and measurement of MMP, cellular ATP levels and 
lysosomal number 
iNPC’s were generated from 3 sPD patient fibroblasts and 3 controls (age +/- SD; controls 54.3 
+/- 4; sPD 52.3 +/-3; each group comprised of 2 males and 1 female donor) as previously 
described (Meyer et al, 2014). iNPC’s were maintained in DMEM/Ham F12 (Invitrogen); N2, 
B27 supplements (Invitrogen) and FGFb (Peprotech) in fibronectin (Millipore) coated tissue 
culture dishes and routinely subcultured every 2-3 days using accutase to detach them. For the 
generation of TH-positive neurons, iNPCs were plated in a 6-well plate and cultured for 2 days 
in DMEM/F-12 medium with Glutamax supplemented with 1%NEAA, 2%B27 (Gibco) and 
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2.5µM of DAPT. On day 3, DAPT was removed and the medium was supplemented with 1µM 
smoothened agonist (SAG) and FGF8 (75ng/ml) for additional 10 days. Subsequently SAG 
and FGF8 were withdrawn and replaced with BDNF (30 ng/ml), GDNF (30 ng/ml), TGF-b3 
(2 mM) and dcAMP (2 mM, Sigma) for 15 days. In order to verify generation of DA neurons, 
immunocytochemistry was performed. Cells were plated into 96 well plates and fixed using 
4% paraformaldehyde for 30 minutes. After PBS washes, cells were permeabilised using 0.1% 
Triton X-100 for 10 minutes and blocked using 5% goat serum for 1 hour. Cells were incubated 
with primary antibodies (tyrosine hydroxylase (Abcam); β III tubulin (Millipore); at 4 degrees 
for 16 hours. Cells are washed using PBS-Tween and incubated with Alexa Fluor conjugated 
secondary antibodies 488 and 568 (Invitrogen) and Hoescht (Sigma) 1µM prior to imaging. 
Imaging was performed using the Opera Phenix high content imaging system (Perkin Elmer). 
Neurons were incubated with 0.1mg/ml Neurosensor 521 for 30 minutes before removal and 
of the dye and imaging using high content imager InCell 2000 using green excitation and 
emission filters. 
At end stage of differentiation neurons were plated in 96 well plates (10,000 neurons per well); 
for live imaging cells were incubated for one hour at 37o with 80 nM tetramethlyrhodamine, 
(TMRM), 100nM LysoTracker Green (Life Technologies) and Hoescht (Sigma) at 1µM before 
imaging using Opera Phenix. Twenty fields of view were imaged, in 7 z planes. Images were 
analysed using Harmony software (Perkin Elmer) using maximal z projections. Mitochondria 
and lysosomes were segmented and the intensity of the mitochondrial signal was normalised 
to the total area of cells in a particular field of view. Cellular ATP measurements were 





2.8. Drug treatment  
A sub-group of patients with mild mitochondrial impairment (either ATP levels (n=3) or MMP 
levels (n=3) > 2 SD but < 3SD below the mean of the control cohort respectively) were assessed 
after treatment with UDCA. The average age of these otherwise randomly selected six sPD 
patients was 53±2.5 years, the average age of the matched controls was 54±4.0 years.  24 hours 
before assaying fibroblasts were changed into galactose media containing either DMSO only 
or 10uM UDCA to determine the effect on MMP, intracellular ATP levels and complex I/IV 
activity (see above). 
 
2.9. Statistics 
Values from multiple experiments were expressed as mean +/- SD. Statistical analysis was 
performed using GraphPad Prism. Individual parameters were assessed with two-tailed 
unpaired t-tests apart from untreated versus treated groups which were compared using a paired 
t test due to the 1:1 matching on age. Mann Whitney U non-parametric test was used between 
control and sPD selected groups where the assumption of normality was not valid. Correlation 
was determined using Pearson’s correlation coefficients. Statistical significance in grouped 
analyses were assessed using two-way ANOVA with Bonferroni post hoc correction. 
Variances were compared using an F-test.  All data was expressed as % of controls unless 
otherwise stated.  Comparisons were declared to be statistically significant at a 5% significance 





3.1. Mitochondrial function  
There was no overall difference in sample means between the entire sPD cohort and the control 
group for either ATP (patients 100.84±12.48, controls 100.76±6.76; p=0.97) or MMP (patients 
106.89±22.49, controls 100.84±14.99; p=0.087). However, as can be seen from Figs 1A and 
1B, the variability in ATP and MMP was larger in sPD patients compared to controls (F-test, 
p<0.0001 for ATP and p=0.0021 for MMP).  In particular 12/100 sPD patients had ATP levels 
reduced by >2SD with four sPD patients having ATP levels >3SD lower than the control mean 
(Fig. 1A). 5/100 sPD patients had MMP levels >2SD lower than the mean of the controls (Fig. 
1B). Total cellular ATP and MMP were not correlated with age of onset (Fig. 1C, D), or disease 
duration (Fig. 1E, F). There was also no correlation with age at the time of biopsy (data not 
shown). 
To further characterize the underlying mechanisms leading to impaired mitochondrial function, 
electron transport chain (ETC) protein levels were assessed via western blotting in the five 
patients with the most marked decrease in ATP levels (mito-sPD) alongside five closely age-
matched controls (see Supplementary Figure 1 for representative Western Blot image). These 
patients showed a decrease in NDUFB8 (complex I) and COX2 (complex IV) protein levels 
(NDUF8 - patients 59.73±18.72, controls 100.00±16.8; p<0.05; COX2 – patients 56.93±20.57; 
controls 100.00±25.42; p<0.05). No differences were observed in the other complexes 
(complex II/SDHB - patients 72.32±21.15, controls 100.00±19.41; p>0.05; complex 
III/UQCRC2 - patients 106.73±15.42, controls 100±42.43; p>0.05; complex V/ATP5A - 
patients 104.33±15.32, controls 100.00±26.41; p>0.05; Fig. 1G). To further evaluate the effect 
of this decrease, NDUF8 and COX2 protein levels were plotted against ATP levels for each 
patient and control and correlation coefficients and linear regressions produced. Plots and 
correlation coefficients suggested that the observed lower ATP levels may at least partially be 
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due to decreased NDUF8 and COX2 protein levels (NDUF8– R2=0.55; p<0.05; COX2 – 
R2=0.46; p<0.05; Fig. 1H).  
 
3.2. Lysosomal dysfunction 
Both the number of lysosomes (patients 114.16±36.54; controls 100.36±26.91; p<0.05) and 
their total area (patients 118.13±47.09; controls 101.01±33.08; p<0.05) were increased in sPD 
(Fig. 2A-D). 15/100 sPD patients had a lysosome count >2SD greater than the control average. 
In a subgroup of patients (lyso-sPD) with lysosome counts >3SD greater than the control mean, 
confirmatory tests were undertaken, including immunocytochemistry for the lysosomal 
membrane protein LAMP2 and measurement of Cathepsin D activity. LAMP2 
immunocytochemistry confirmed an increase in lysosome number in the assessed patients 
within the lyso-sPD group (patients (n=5) 135.74±17.63; controls (n=5) 100.00±6.1; p<0.001, 
Fig. 2E). Cathepsin D activity was then correlated with the number of lysosomes.  A marked 
decrease in Cathepsin D activity per lysosome was seen in lyso-sPD, suggesting lysosomal 
dysfunction (patients 49.62±5.74; controls 100.00±49.79; p<0.05, Fig. 2F). The number of 
lysosomes were not correlated with age at the time of biopsy, age of onset or disease duration 
(data not shown). Supplementary table 2 summarizes the MMP, ATP and lysosome count 
number for all research participants. 
The change in Cathepsin D activity is specific to the identified lysosomal sub-group as we 
measured the Cathepsin D activity in the mitochondrial sub-group and found no difference to 





3.3. Pathway analysis 
In the two subgroups of sPD patients with either lysosomal count >3SD (lyso-sPD, n=5) or 
reduced ATP levels >3SD (mito-sPD, n=5), RNAseq-based differential gene expression 
analysis revealed 342 genes that were differentially expressed in lyso-sPD compared to age-
matched controls. Conversely, 84 genes reached significance in mito-sPD. There was no 
overlap in differentially expressed genes (DEG) between the two subgroups. The top 10 results 
for the lyso-sPD group from the gene-disease phenotype association tool VarElect (Stelzer et 
al., 2016) indicate a number of these DEGs have established associations with both PD and the 
lysosome (Table 1, see also Supplementary Table 3 for complete list of all differentially 
expressed genes for lyso-sPD vs controls meeting an adjusted p value < 0.05).  
 
Enrichment analysis revealed enrichment for a number of signalling pathways, the KEGG 
pathways; “TNF signalling” and “Lysosome” were most markedly impaired (Table 2). Of the 
10 genes overlapping with this lysosome pathway, 9 were upregulated in patients (Table 3). 
The single downregulated gene, LITAF, is likely due to zero counts detected for all four 
patients, which explains its high fold change value. 
 
In contrast, the 84 DEGs associated with mito-sPD did not enrich for any functions or pathways 
and therefore failed to identify any pathways associated with mitochondrial dysfunction. To 
identify the presence of an underpowered signal, the p value threshold was relaxed to include 
genes which only achieved an unadjusted p value of <0.05 for both conditions. Six hundred 
and thirty overlapping genes were removed, leaving 1659 DEGs for VarElect analysis in the 
mito-sPD group. This exploratory approach identified SNCA and PLA2G6 as the genes with 
the highest VarElect score (Table 4, see also Supplementary Table 4 for complete list of all 
differentially expressed genes for mito-sPD vs controls meeting an adjusted p value < 0.05).  
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3.4. Genetic analysis  
Shulman and co-workers had previously reported an excessive burden of gene variants in 54 
LSD genes in PD (Robak et al., 2017). We hypothesised that there would be an enrichment of 
LSD gene variants in the stratified patient cohort which displayed lysosomal dysfunction and 
related changes in the RNAseq-based pathway analysis. NeuroChip-based genotyping for 
sequence variants in the same LSD genes previously investigated by Shulman and colleagues 
(Supplementary Table 5a) did not identify an overall difference in the number of individuals 
carrying one or more damaging LSD variants between the entire PD cohort and controls (PD: 
17/99 carrying one damaging LSD variant (17.2%), one of these PD patients carried a second 
variant; controls: 7/50 (14%) damaging LSD variants; p value of Fisher’s exact test = 0.64). 
However, the proportion of PD patients carrying an LSD damaging variant rose to 5/14 (35%, 
p value of Fisher’s exact test = 0.060) for the group of patients with a lysosomal count of > 2 
SD and to 3/5 (60%, p value of Fisher’s exact test = 0.031) in the patients with a lysosomal 
count of  > 3SD (Supplementary Table 5b).  
 
3.5. Mitochondrial and lysosomal abnormalities are confirmed and further exacerbated in 
TH-positive neurons generated from a subset of sPD patients 
TH-positive neurons were differentiated from iNPC’s (i-neurons) derived from fibroblasts of 
3 sPD patients and 3 controls. We determined the neuronal properties by assessing changing 
morphology, immunostaining for several neuronal markers and qPCR. The neurons become 
more elongated and form connections at the later stages of differentiation, as shown by the 
representative images of a control and sPD line at day 27 of differentiation (Figure 3A (i) and 
(ii)). We stained for general neuronal markers, β III tubulin and Map2. As can be seen in the 
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representative images in Figure 3A (iii) and (iv)  both control (iii) and sPD (iv) neurons stained 
positively for βIII tubulin. Figure 3A (v) and (vi) show images for positive staining of a control 
(v) and sPD (vi) line of Map2. Furthermore we assessed the expression of DA neuron markers 
such as TH and DAT. Figure 3B (i) and (ii) show representative images of TH staining in a 
control (i) and sPD (ii) line. Representative images of TH staining for the remaining four i-
neuron cell lines are shown in Supplementary Figure 3. The expression level was also 
quantified; with no difference between the control and sPD (Figure 3B (vi)). In addition, we 
used qPCR to quantify the TH expression levels in iNPC’s and iNeurons. We see a 3.4 fold 
increase in TH expression in the iNeurons (Figure 3B (v)). In addition to TH we assessed 
expression of DAT; with representative images shown in Figure 3B (iii) of a control and (iv) 
for sPD; showing clear overall expression in most cells of both control and sPD.  
Fibroblasts from sPD patients within this subgroup had a reduction in cellular ATP levels or 
MMP of  >2SD from the control mean; with a mean reduction in cellular ATP levels in the 
fibroblasts of 15% and a mean reduction of MMP in the fibroblasts of 21% in this group. 
Cellular ATP levels in the DA i-neurons were reduced by 59.7% compared to controls (mean 
+/- SD; controls: 100.1 +/- 33.5; sPD: 40.29 +/- 20.24, ** p < 0.05, Figure 3C (iii)). Similarly, 
MMP quantification also revealed enhanced deficits in the sPD patient derived TH-positive i-
neurons with MMP decreased by 44.5% compared to controls (mean +/- SD; controls: 8208 
+/- 577; sPD: 4643 +/- 678; *** p < 0.01). Example images of the MMP in a control and sPD 
TH-positive neuron line are shown in Figure 3C (i) and (ii); the intensity of the TMRM signal 
is clearly reduced in the sPD TH-positive neurons. 
We also assessed the lysosomal number in these DA i-neurons; in this group of sPD patient 
fibroblasts, the lysosome number was increased by 6.5%; whereas in the TH-positive i-neurons 
derived from the same sPD patient group lysosome number was increased by 71% compared 
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to controls (% normalised to controls shown as mean +/- SD; controls 100 +/- 22.8; sPD 171.8 
+/- 36.4; * p < 0.05, Figure 3C (v)).   
 
3.6. Treatment response in stratified patient tissue  
Finally, we sought to discover whether UDCA had a recovery effect on mitochondrial 
respiratory chain function in stratified sPD tissue comparable to the beneficial effect observed 
in genetically stratified, parkin or LRRK2G2019S mutant tissue (Mortiboys et al., 2013; 
Mortiboys et al., 2015). UDCA and its taurine conjugate tauroursodeoxycholic acid (TUDCA) 
are thought to exert a neuroprotective effect via Akt activation (Castro-Caldas et al., 2012; 
Chun and Low, 2012; Mortiboys et al., 2013). As severe mitochondrial impairment was 
comparatively rare in the overall sPD patient group, we selected a group of six sPD patient 
fibroblasts with mildly impaired mitochondrial function (ATP or MMP levels > 2 SD but < 3 
SD below the mean of controls) in order to assess the potential of UDCA treatment to be 
beneficial in a larger patient population. As predicted, treatment of these mechanistically 
stratified sPD fibroblasts with 10 µM UDCA for 24 hours increased cellular ATP levels up to 
103% and MMP up to 92% of control levels (Fig. 4A, B; p < 0.01). Individual respiratory chain 
measurements identified a decrease of 75% in complex I activity (Fig. 4C, p < 0.001) and a 
decrease of 37% in complex IV activity in the selected sPD patients (Fig. 4D, p < 0.01). 
Treatment with UDCA increased both complex I and complex IV activity to 80% of control 




Precision medicine has already become reality in some areas of medical care such as non-small 
cell lung cancer (Li et al., 2013), where the choice of treatment regime is guided by the specific 
underlying genetic cause in a given patient. Genetic stratification may be a particularly 
promising approach for certain subtypes of PD as well, the first phase II drug trials focussing 
on PD patients carrying GBA1 mutations are under way (NCT02906020; NCT02914366) 
(Gasser, 2015). However, genetic stratification is unlikely to be applicable to the majority of 
PD patients in the UK and elsewhere with only 1% of sPD patients who present at a typical age 
and carry Mendelian PARK gene mutations (Tan et al., 2019). Doubts whether genetic 
stratification of common disorders will fulfil the promise of precision medicine have also been 
cast in other areas of medicine (Joyner and Paneth, 2019). Precision medicine focussing on 
mechanistically anchored disease subgroups may therefore hold greater promise (Rosen and 
Zeger, 2019). We now demonstrate the utility of using skin fibroblasts to undertake such 
mechanistic stratification in sPD. The proposed stratification approach may offer particular 
value in neuroprotective treatment trials assessing the effect of a mitochondrial or lysosomal 
rescue agent on disease progression in sPD. However, we acknowledge that larger cohorts need 
to be assessed to confirm our findings. A further limiting aspect of our approach is the invasive 
nature of skin biopsies which may limit a potential adaption into routine clinical care. Future 
studies need to determine whether fibroblasts could be replaced or combined with other, less 
invasive strategies such as advanced imaging techniques or assessment of mitochondrial 
function in blood monocytes (Hattingen et al., 2009; Smith et al., 2018).   
The absence of any marked group differences (with the possible exception of lysosomal 
dysfunction) between the entire sPD cohort and the control cohort supports the assumption of 
aetiological heterogeneity in sPD. The presence of a LRRK2G2019S in one patient and of GBA1 
mutations in two further patients did not allow a prediction of their cellular phenotype.  
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Our results are in keeping with a recently proposed, elegant concept of biomarker-driven 
phenotypes for sPD (Espay et al., 2017). Espay and co-workers proposed a model of 
biomarker-defined, homogenous subtypes of PD likely to respond optimally to therapies 
proven to affect the causative biological processes within each subtype. They suggested a re-
evaluation of the biomarker-discovery effort for sPD, using abnormal biological signals (rather 
than clinical definitions) to define disease phenotypes. Their proposed exploratory approach, 
based on a systems-biology model with abnormal biological signals defined as >2SD above or 
below the mean to identify biologically defined subgroups is strikingly comparable to the 
approach used and the data obtained in our study. 
Our RNAseq-based pathway analysis in the lyso-sPD subgroup strongly suggested that the 
observed lysosomal dysfunction is associated with an upregulation of lysosomal transcriptional 
networks and identified a number of lysosomal genes/proteins previously associated with PD 
such as SMPD1 or RAB7A. The increase in the transcript levels of crucial lysosomal genes 
may be a compensatory mechanism for impaired lysosomal function in the lyso-sPD subgroup, 
reflected by the reduced Cathepsin D enzymatic activity per lysosome in this group. The 
noticeable enrichment for LSD gene variants in the lyso-sPD group suggests that the observed 
lysosomal dysfunction is at least partially driven by genetic factors. However, replication in a 
considerably larger cohort are required to confirm the apparent association between LSD gene 
variants and lysosomal dysfunction in peripheral tissue of sPD patients.  
In contrast, there was a noticeable absence of pathway enrichment in the RNAseq analysis of 
the mito-sPD group. This suggests that the observed mitochondrial dysfunction is neither due 
to transcriptionally regulated pathways nor does the reduced ATP production appear to result 
in compensatory changes at the transcriptional level. The observed upregulation of SNCA and 
PLA2G6 as well as other genes such as APP (table 4) previously implicated in PD or other 
neurodegenerative diseases has to be interpreted with caution since these genes were only 
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upregulated when the p value threshold was relaxed to include genes which achieved an 
unadjusted p value of <0.05. We acknowledge that the observed mitochondrial and lysosomal 
dysfunction as well as the associated gene expression changes in the lyso-sPD group may only 
be epiphenomena due to interaction with other biological mechanisms. However, we propose 
that it is still plausible to assume that patients in the mito-sPD and lyso-sPD subgroups are 
more likely to benefit from putative neuroprotective compounds focussing on the rescue of 
mitochondrial or lysosomal function respectively.  
Direct conversion of fibroblasts to iNPCs and subsequent differentiation to DA neurons 
provides a fast methodology to obtain high-yield of specialised neurons from somatic cells 
while retaining the genetic background of the donor and avoiding the clonal expansion typical 
for stem-cell derived neurons (Meyer et al., 2014). This significantly improves the 
reproducibility of the data, as each iNPC line is representative of the donor without having to 
select or compare individual clones. The confirmation of mitochondrial or lysosomal 
abnormalities in TH-positive i-neurons derived from sPD fibroblasts is in keeping with the 
hypothesis that the observed abnormalities in the peripheral tissue would also be present in the 
brains of the respective sPD patients. To our knowledge, indices of mitochondrial or lysosomal 
dysfunction in peripheral tissue from sPD patients have never been compared to mitochondrial 
or lysosomal dysfunction in peripheral tissue-derived inducible TH-positive i-neurons from the 
same patient. The markedly enhanced abnormalities in the TH-positive i-neurons suggests that 
even comparatively mild abnormalities in skin fibroblasts may reflect significant impairment 
in neuronal tissue. The reasons we see the enhanced phenotype in the i-neurons could be due 
to the metabolic status of the cells; neurons heavily reliant on OXPHOS to maintain energy 
levels; in addition to the expression of disease relevant proteins such as alpha synuclein in the 
neurons as opposed to fibroblasts. A similar phenomenon were observed in Friedreich’s Ataxia 
and motor neuron disease (Georges et al., 2019; Vandoorne et al., 2019). Further studies are 
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necessary to compare and possibly combine the different approaches assessing mitochondrial 
or lysosomal function in peripheral tissue in sPD (Atashrazm et al., 2018; Papagiannakis et al., 
2015; Shamir et al., 2017; Smith et al., 2018). The observation of abnormalities in non-
neuronal tissue may reflect strong genetic determinants but is also in keeping with other, more 
speculative hypotheses such as PD being a generalized metabolic disorder which 
predominantly affects (but is not limited to) DA neurons.  
We predict that ex vivo testing of putative neuroprotective compounds in individual sPD patient 
tissue (fibroblasts, i-neurons or alternative approaches) will soon become a routine part of the 
initial triaging process for mechanistically defined multi-arm neuroprotection trials in sPD. The 
beneficial effect of UDCA in sPD patient tissue reported here is comparable to the effect we 
previously observed in genetically stratified PD patient tissue (Mortiboys et al., 2013; 
Mortiboys et al., 2015). We are now undertaking a phase II, proof of concept study to establish 
safety and tolerability of UDCA at a dose of 30 mg/kg in sPD and explore its neuroprotective 
potential (clinicaltrials.gov NCT03840005).  
In conclusion, we acknowledge that our work has only identified distinct pathomechanisms in 
some but not all sPD fibroblast lines. However, our data nevertheless suggest that in-depth 
phenotyping of peripheral tissue can be helpful in moving towards mechanistic disease 
stratification and precision medicine approaches in sPD.  
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Gene Name Matched Phenotypes VarElect 
Score 
CTSD Cathepsin D Parkinson’s Disease, 
Lysosome 
59.51 
SMPD1 Sphingomyelin Phosphodiesterase 1 Parkinson’s Disease, 
Lysosome 
56.85 
FUCA1 Alpha-L-Fucosidase 1 Parkinson’s Disease, 
Lysosome 
45.44 





MAPK3 Mitogen-Activated Protein Kinase 3 Parkinson’s Disease, 
Lysosome 
34.54 





IGF2 Insulin Like Growth Factor 2 Parkinson’s Disease, 
Lysosome 
23.58 
ALDH1A1 Aldehyde Dehydrogenase 1 Family 
Member A1 
Parkinson’s Disease 21.85 
MSX1 Msh Homeobox 1 Parkinson’s Disease 19.67 





Table 1: Top 10 results for lysosomal-dysfunctional DEGs from VarElect. Investigation 
of DEGs using online tool VarElect with the terms “Lysosome” and “Parkinson’s Disease” 
indicates a number of genes score highly for association with these terms. Gene symbol 
represents official HGNC symbol. Matched Phenotypes indicates the terms inputted into 













0.004103 MAP2K3, NFKBIA, IKBKB, TAB2, 




0.005396 PLA2G15, CD63, ATP6V0B, NPC1, 
SORT1, FUCA1, SMPD1, LITAF, 
CTSD, ATP6V0A1 




0.007545 NFKBIA, ITGB1, IKBKB, CDKN1B, 











0.010408 MAP2K3, ITGB1, KITLG, PLCB4, 
PRKD3, PDGFD, ITGB2, GNAS, 
RAPGEF5, RAPGEF6, FGF2, MAPK3 
 
Table 2: Top 5 most enriched KEGG pathways for lysosome-dysfunctional DEGs. 
Results indicate an enrichment of signalling pathways as well as the pathway “Lysosome”. 
Overlap indicates number of genes in input list/total number of genes in pathway list. 





Gene Name Fold 
Change 
P Value Adjusted P 
Value 
PLA2G15 Phospholipase A2 Group XV 1.67 7.56E-15 1.06E-10 
CTSD Cathepsin D 2.54 1.80E-07 0.00017135 
FUCA1 Alpha-L-Fucosidase 1 2.89 2.12E-05 0.0075658 
SMPD1 Sphingomyelin Phosphodiesterase 1 1.89 5.65E-05 0.01389979 
ATP6V0
B 
ATPase H+ Transporting V0 
Subunit B 
1.62 7.09E-05 0.01636507 
CD63 CD63 Molecule 1.69 0.00011924 0.02430102 
LITAF Lipopolysaccharide Induced TNF 
Factor 
-142.71 0.00012847 0.02535096 
ATP6V0
A1 
ATPase H+ Transporting V0 
Subunit A1 
1.73 0.00013745 0.02665443 
SORT1 Sortilin 1 3.71 0.00020504 0.03480873 
NPC1 NPC Intracellular Cholesterol 
Transporter 1 
3.26 0.00021755 0.03554635 
 
Table 3: Fold change and P-values for the 10 DEGs which enrich within the KEGG 
pathway “Lysosome”. Upregulation of expression was observed for most genes except the 
gene LITAF which shows downregulation. P Values and Adjusted P Values are as reported 




Gene Name Matched Phenotypes VarElect 
Score 
SNCA Synuclein Alpha Parkinson’s Disease, 
Mitochondria 
318.70 
PLA2G6 Phospholipase A2 Group VI Parkinson’s Disease, 
Mitochondria 
99.07 
RPS27A Ribosomal Protein S27a Parkinson’s Disease, 
Mitochondria 
63.08 
PODXL Podocalyxin Like Parkinson’s Disease, 
Mitochondria 
53.55 
NDUFS2 NADH:Ubiquinone Oxidoreductase 




GCH1 GTP Cyclohydrolase 1 Parkinson’s Disease, 
Mitochondria 
52.80 
APP Amyloid Beta Precursor Protein Parkinson’s Disease, 
Mitochondria 
49.75 
PANK2 Pantothenate Kinase 2 Parkinson’s Disease, 
Mitochondria 
49.62 
NDUFS1 NADH:Ubiquinone Oxidoreductase 




NDUFAF5 NADH:Ubiquinone Oxidoreductase 






Table 4: Top 10 results for unadjusted mitochondrial-dysfunctional DEGs from 
VarElect. Investigation of DEGs using online tool VarElect with the terms “Mitochondria” 
and “Parkinson’s Disease” in mito-sPD compared to controls indicates a number of genes 
score highly for association with these terms, including well-established PD genes. Gene 
symbol represents official HGNC symbol. Matched Phenotypes indicates the terms inputted 















Figure 1: Cellular ATP and mitochondrial membrane potential in sPD patients. Total 
cellular ATP levels (A) and mitochondrial membrane potential (MMP) (B) in 100 sPD patients 
(red circles) and age-matched control participants (blue circles). 12 sPD patients had ATP 
levels > 2SD (fine dashed line) lower than controls with ATP levels > 3 SD (thick dashed line) 
in four of these sPD patients. The sPD patient carrying a LRKK2G2019S mutation is depicted 
with a green circle, the two patients carrying GBA1 mutations are depicted with orange circles 
(A, B). The average ATP and MMP levels previously detected in LRKK2G2019S mutant 
fibroblasts are indicated for comparison with a green line (Mortiboys et al. 2010). Neither ATP 
(C,E) nor MMP (D, F) correlated with either age at disease onset or disease duration since 
diagnosis, (G) NDUFB8 (complex I) and COX2 (complex IV) protein levels were reduced in 
the subset of the five sPD patients with the lowest intracellular ATP levels compared to  age-
matched controls (NDUFB8 - sPD 59.73±18.72, controls 100±16.8; p<0.05; COX2 – sPD 
56.93±20.57; controls 100±25.42; p<0.05). In contrast, complex II/SDHB (sPD 72.32±21.15, 
controls 100±19.41; p>0.05; complex III/UQCRC2 (sPD 106.73±15.42, controls 100±42.43; 
p>0.05) and complex V/ATP5A (sPD 104.33±15.32, controls 100±26.41; p>0.05) protein 
levels were normal. (H) The observed reduction in NDUFB8/Complex I (circles/solid line) and 
COX2/complex IV (triangle/dashed line) protein levels correlated with the reduction in ATP 




Figure 2: Assessing lysosomes in sPD patients. The number and area of lysosomes were 
quantified in sPD patients (n=100; red circles) and age-matched control participants (n=50; 
blue circles) by (A) staining fibroblasts with LysotrackerRed (lysosomes; red) and Hoechst 
(nuclei; blue) with subsequent (B) segmented image analysis using the Developer software 
(scale bar = 10µM). Both the number of lysosomes (sPD 114.2±36.54; controls 100.4±26.91; 
p<0.05, C) and their total area (sPD 118.1±47.09; controls 101.0±33.08; * p<0.05, D) were 
increased in sPD (thin dashed line – 2SD; thick dashed line – 3SD). The sPD patient carrying 
a LRKK2G2019S mutation is depicted with a green circle, the two patients carrying GBA1 
mutations are depicted with orange circles. LAMP2 immunocytochemistry confirmed an 
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increase in lysosome number in the five sPD patients with the most marked increase in 
lysosome number (sPD 135.74±17.63; controls 100±6.1; *** p<0.001, E). In contrast, 
Cathepsin D activity was decreased, suggesting lysosomal dysfunction with compensatory 





Figure 3: (A) Characterisation of fibroblast-derived TH-positive neurons. Representative 
images of control (i, iii, v) and sPD (ii, iv, vi) derived TH-positive neurons at the end stage of 
differentiation brightfield (i) and (ii); stained for βIII tubulin (green) and Hoechst (nuclei, 
blue; iii and iv) and Map2 (green) and Hoechst (nuclei, blue; (v and vi)).  
(B) Representative images of control (i;iii) and sPD (ii;iv) neurons at the end stage of 
differentiation stained for tyrosine hydroxylase (red) and Hoechst (nuclei, blue i and ii). 
Panels (iii) and (iv) have been stained with DAT (red), Hoechst (nuclei, blue). (v) TH mRNA 
expression was assessed in iNPC’s and end stage iNeurons, showing a 3.4 fold increase in 
TH expression. (vi) TH expression levels were quantified from controls and sPD iNeurons, 
with no differences found. 
(C) Panels (i) and (ii) show representative images of TMRM stained mitochondria and 
lysotracker stained lysosomes in iNeurons from a control (i) and an sPD patient (ii) (red is 
mitochondria, green is lysosomes and blue nuclei). (iii) Cellular ATP levels are reduced by 
59.7% in sPD dopaminergic neurons, ** p < 0.05. (iv) MMP is similarly reduced in sPD 
dopaminergic neurons by 44.5%, *** p < 0.01. (v) Lysosome number is increased in sPD 
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dopaminergic neurons by 71%, * p < 0.05. Neurons were differentiated from 3 controls and 3 




Figure 4: Recovery of mitochondrial deficits after UDCA treatment in sPD patient 
fibroblasts. (A) UDCA treatment increases cellular ATP in sPD fibroblasts (red bars, n=6) to 
103% of control levels (blue bars, n=6, ** p < 0.01) and (B) the mitochondrial membrane 
potential (MMP) to 92% of controls (*** p < 0.001). (C) Individual respiratory chain 
measurements identified a decrease of 75% in complex I activity (*** p < 0.001) and (D) a 
decrease of 37% in complex IV activity (** p < 0.01) in the selected sPD patient fibroblasts 
lines. Treatment with UDCA increased both complex I (C) and complex IV (D) activity to 80% 
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